IVERIC bio, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2020-11-02: Form 8-K; Period of report 2020-11-02; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2020-08-05: Form 8-K; Period of report 2020-08-05; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2020-07-17: Form 8-K; Period of report 2020-07-15; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2020-06-19: Form 8-K; Period of report 2020-06-17; Description 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2020-11-02 | 8-K | 2020-11-02 | 2.02 Results of Operations and Financial Condition | 2.02 On November 2, 2020, IVERIC bio, Inc. announced its financial results for the three and nine months ended September 30, 2020. | isee-20201102.htm |
| 2020-08-05 | 8-K | 2020-08-05 | 2.02 Results of Operations and Financial Condition | 2.02 On August 5, 2020, IVERIC bio, Inc. announced its financial results for the three and six months ended June 30, 2020. | isee-20200805.htm |
| 2020-07-17 | 8-K | 2020-07-15 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 15, 2020, the Board of Directors (the “Board”) of IVERIC bio, Inc. (the “Company”) increased the size of the Board from six to seven members and elected Dr. Mark S. Blumenkranz as a director of the Company, effective immediately. | a8-kxdrblumenkranz.htm |
| 2020-06-19 | 8-K | 2020-06-17 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 3.02 The information contained in Item 1.01 under the heading “Stock Purchase Agreement” is hereby incorporated by reference into this Item 3.02. 8.01 The Company issued a press release announcing the pricing of the Public Offering on June 18, 2020, which press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference. | tm2022716d6_8k.htm |
| 2020-06-17 | 8-K | 2020-06-17 | 8.01 Other Events | 8.01 Iveric bio, Inc. (the “Company”) is filing, as Exhibit 99.1 hereto, updated risk factors relating to the Company’s business. | tm2022716d3_8k.htm |
| 2020-06-15 | 8-K | 2020-06-15 | 8.01 Other Events | 8.01 On June 15, 2020, the Company issued a press release announcing the 18 month results of its Phase 3 clinical trial of Zimura® (avacincaptad pegol), the Company’s complement factor C5 inhibitor, in patients with geographic atrophy ("GA") secondary to age-related macular degeneration (the "OPH2003 trial"). | a8-kx2020clinicaltrial.htm |
| 2020-06-10 | 8-K | 2020-06-09 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 IVERIC bio, Inc. ("IVERIC") held its 2020 annual meeting of stockholders on June 9, 2020. | a8-kx2020agm.htm |
| 2020-05-06 | 8-K | 2020-05-06 | 2.02 Results of Operations and Financial Condition | 2.02 On May 6, 2020, IVERIC bio, Inc. announced its financial results for the quarter ended March 31, 2020. | item2028k.htm |
| 2020-03-18 | 8-K | 2020-03-18 | 8.01 Other Events | 8.01 The Company today announced that due to the threat of the coronavirus (COVID-19) global pandemic, the Company has decided to delay the initiation of enrollment of patients in the second pivotal clinical trial (the "ISEE2008 trial") for Zimura® (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). | a8k.htm |
| 2020-02-27 | 8-K | 2020-02-27 | 2.02 Results of Operations and Financial Condition | 2.02 On February 27, 2020, IVERIC bio, Inc. announced its financial results for the quarter and year ended December 31, 2019. | a8-k.htm |
| 2020-01-13 | 8-K | 2020-01-13 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2019, the Company will announce during the 38th Annual J.P. Morgan Healthcare Conference, which begins on January 13, 2020, that it expects to report that it had approximately $126 million in cash and cash equivalents as of December 31, 2019. 8.01 The information in Item 2.02 of this Form 8-K is incorporated by reference. | isee2008trialdesign8k.htm |